For example, in breast cancer, MYC-driven epigenetic reprogramming causes activation of de novo enhancers to support dedifferentiation and onset of a stem-like state while repressing transcriptional activity of lineage-specifying transcription factors [19]. Here, MYC is linked to breast carcinoma.